Glycemic Control Of Carvedilol Versus Metoprolol In Patients With Type II Diabetes Mellitus And Hypertension
Public ClinicalTrials.gov record NCT00060918. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Multicenter Study Comparing the Glycemic Control Characteristics of Carvedilol and Metoprolol in Hypertensive Patients With Type II Diabetes Mellitus.
Study identification
- NCT ID
- NCT00060918
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- GlaxoSmithKline
- Industry
- Enrollment
- 1,210 participants
Conditions and interventions
Conditions
Interventions
- carvedilol Drug
- metoprolol Drug
Drug
Eligibility (public fields only)
- Age range
- 30 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2001
- Primary completion
- Mar 31, 2004
- Completion
- Mar 31, 2004
- Last update posted
- Apr 14, 2015
2001 – 2004
United States locations
- U.S. sites
- 50
- U.S. states
- 20
- U.S. cities
- 46
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Glendale | Arizona | 85306 | — |
| GSK Investigational Site | Phoenix | Arizona | 85016 | — |
| GSK Investigational Site | Phoenix | Arizona | 85050 | — |
| GSK Investigational Site | Tucson | Arizona | 85724 | — |
| GSK Investigational Site | Burlingame | California | 94010 | — |
| GSK Investigational Site | Concord | California | 94520 | — |
| GSK Investigational Site | Encinitas | California | 92024 | — |
| GSK Investigational Site | Hemet | California | 92543 | — |
| GSK Investigational Site | Long Beach | California | 90806 | — |
| GSK Investigational Site | Orange | California | 92868 | — |
| GSK Investigational Site | Pasadena | California | 91105 | — |
| GSK Investigational Site | Riverside | California | 92501 | — |
| GSK Investigational Site | San Diego | California | 92102 | — |
| GSK Investigational Site | San Luis Obispo | California | 93405 | — |
| GSK Investigational Site | Spring Valley | California | 91978 | — |
| GSK Investigational Site | Aurora | Colorado | 80045 | — |
| GSK Investigational Site | Denver | Colorado | 80220 | — |
| GSK Investigational Site | Golden | Colorado | 80401 | — |
| GSK Investigational Site | Panama City | Florida | 32401 | — |
| GSK Investigational Site | St. Petersburg | Florida | 33701 | — |
| GSK Investigational Site | Honolulu | Hawaii | 96813 | — |
| GSK Investigational Site | Idaho Falls | Idaho | 83404 | — |
| GSK Investigational Site | Chicago | Illinois | 60612 | — |
| GSK Investigational Site | O'Fallon | Illinois | 62269 | — |
| GSK Investigational Site | Elkhart | Indiana | 46515 | — |
| GSK Investigational Site | Indianapolis | Indiana | 46260 | — |
| GSK Investigational Site | Iowa City | Iowa | 52242 | — |
| GSK Investigational Site | Kalamazoo | Michigan | 49009 | — |
| GSK Investigational Site | Oak Park | Michigan | 48237 | — |
| GSK Investigational Site | Minneapolis | Minnesota | 55417 | — |
| GSK Investigational Site | Kansas City | Missouri | 64106 | — |
| GSK Investigational Site | Kansas City | Missouri | 64111 | — |
| GSK Investigational Site | St Louis | Missouri | 63110 | — |
| GSK Investigational Site | St Louis | Missouri | 63128 | — |
| GSK Investigational Site | Las Vegas | Nevada | 89103 | — |
| GSK Investigational Site | Albuquerque | New Mexico | 87131 | — |
| GSK Investigational Site | Oklahoma City | Oklahoma | 73112 | — |
| GSK Investigational Site | Bend | Oregon | 97701 | — |
| GSK Investigational Site | Oregon City | Oregon | 97045 | — |
| GSK Investigational Site | Dallas | Texas | 75390 | — |
| GSK Investigational Site | Fort Worth | Texas | 76104 | — |
| GSK Investigational Site | Georgetown | Texas | 78626 | — |
| GSK Investigational Site | Midland | Texas | 79705 | — |
| GSK Investigational Site | San Antonio | Texas | 78259 | — |
| GSK Investigational Site | San Antonio | Texas | 78299 | — |
| GSK Investigational Site | The Colony | Texas | 75056 | — |
| GSK Investigational Site | Ogden | Utah | 84401 | — |
| GSK Investigational Site | Renton | Washington | 98055 | — |
| GSK Investigational Site | Madison | Wisconsin | 53792 | — |
| GSK Investigational Site | Milwaukee | Wisconsin | 53151 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00060918, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 14, 2015 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00060918 live on ClinicalTrials.gov.